MARCHF6

Across TCGA pan-cancer cohorts, MARCHF6 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MARCHF6 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MARCHF6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MARCHF6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LUAD, and PDAC are the cancer types where MARCHF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.914	0.447	.005	20	view →
LUAD	DFS	Median	All	0.670	0.946	.008	19	view →
PDAC	DFS	Median	All	0.253	0.624	.019	6	view →
LSCC	DFS	Quartile	All	0.356	0.815	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MARCHF6–HNSC (DFS)

Open the HNSC breakdown →